Successful treatment of pure red cell aplasia in systemic lupus erythematosus with erythropoietin.
We describe a 32-year-old woman who developed severe anemia due to pure red cell aplasia in the course of systemic lupus erythematosus (SLE). After failure of therapy with high doses of glucocorticoids and immunoglobulins, and despite high levels of endogenous erythropoietin, she was treated with human recombinant erythropoietin with dramatic and sustained improvement. Based on this case and on the literature review of erythropoietin therapy in pure red cell aplasia, we suggest that erythropoietin should be used in SLE associated pure red cell aplasia before cytotoxic therapy.
Orbach
H
H
Department of Medicine, Hadassah University Hospital, Jerusalem, Israel.
Ben-Yehuda
A
A
Ben-Yehuda
D
D
Manor
D
D
Rubinow
A
A
Naparstek
Y
Y
D000328:Adult; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012010:Red-Cell Aplasia, Pure / Q000188:drug therapy* / Q000209:etiology
D011994:Recombinant Proteins; D004921:Erythropoietin